Cargando…
PRELIMINARY ANALYSIS ON EFFICACY OF RITONAVIR-BOOSTED NIRMATRELVIR ON DISEASE PROGRESSION AMONG HIGH-RISK HOSPITALISED COVID-19 PATIENTS: A RETROSPECTIVE CASE-CONTROL STUDY
INTRO: Ritonavir-boosted nirmatrelvir has shown efficacy in reducing the rate of hospitalisation and 28-day mortality among unvaccinated populations with COVID-19. The role of Ritonavir-boosted nirmatrelvir among high risk hospitalised COVID-19 patients remained uncertain. Our study aimed to assess...
Autores principales: | Lee, S.P., Chuah, C.H., Mak, W.Y., Tan, J.W., Lee, J.N., Bidin, F.N., Leong, K.N., Wong, P.S., Chow, T.S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186958/ http://dx.doi.org/10.1016/j.ijid.2023.04.287 |
Ejemplares similares
-
A COMPARISON OF PULSE METHYLPREDNISOLONE TO LOW-DOSE METHYLPREDNISOLONE IN CRITICALLY-ILL PATIENTS WITH SARS-COV-2 PNEUMONIA: RETROSPECTIVE, OBSERVATIONAL STUDY
por: Bidin, F.N., et al.
Publicado: (2023) -
Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022) -
Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022) -
Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
por: Imran, Laiba, et al.
Publicado: (2023) -
Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)